Path Fertility Receives $2 Million NIH Grant To Develop Epigenetic Diagnostic For Severe Male Infertility
· pulse2.com · popularity 17/100 · 0 similar stories today · Women's & Men's Health (Health & Life Sciences)
Read the original at pulse2.com →
Summary
Path Fertility, the commercial brand of Salt Lake City-based molecular diagnostics company Inherent Biosciences, has received a $2 million research grant from the National Institutes of Health to develop an epigenetic diagnostic test for severe male infertility and associated health risks. The post Path Fertility Receives $2 Million NIH Grant To Develop Epigenetic Diagnostic For Severe Male Infertility appeared first on Pulse 2.0 .
Found in: Pulse 2.0. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 14.